http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Kim, Sun Bean,Kim, Hye Won,Kim, Hyon-Suk,Ann, Hea Won,Kim, Jae Kyoung,Choi, Heun,Kim, Min Hyung,Song, Je Eun,Ahn, Jin Young,Ku, Nam Su,Oh, Dong Hyun,Kim, Yong Chan,Jeong, Su Jin,Han, Sang Hoon,Kim, Ju Informa Healthcare 2014 Scandinavian journal of infectious diseases Vol.46 No.2
<P><I>Background</I>: There have been various efforts to identify less costly but still accurate methods for monitoring the response to HIV treatment. We evaluated a pooling method to determine if this could improve screening efficiency and reduce costs while maintaining accuracy in Seoul, South Korea. <I>Methods</I>: We conducted the first prospective study of pooled nucleic acid testing (NAT) using a 5 minipool + algorithm strategy versus individual viral load testing for patients receiving antiretroviral therapy (ART) between November 2011 and August 2012 at an urban hospital in Seoul, South Korea. The viral load assay used has a lower level of detection of 20 HIV RNA copies/ml, and the cost per assay is US$ 136. The 5 minipool +algorithm strategy was applied and 43 pooled samples were evaluated. The relative efficiency and accuracy of the pooled NAT were compared with those of individual testing. <I>Results</I>: Using the individual viral load assay, 15 of 215 (7%) plasma samples had more than 200 HIV RNA copies/ml. The pooled NAT using the 5 minipool + algorithm strategy was applied to 43 pooled samples; 111 tests were needed to test all samples when virologic failure was defined at HIV RNA ≥ 200 copies/ml. Therefore, 104 tests were saved over individual testing, with a relative efficiency of 0.48. When evaluating costs, a total of US$ 14,144 was saved for 215 individual samples during 10 months. The negative predictive value was 99.5% for all samples with HIV RNA ≥ 200 copies/ml. <I>Conclusions:</I> The pooled NAT with 5 minipool + algorithm strategy seems to be a very promising approach to effectively monitor patients receiving ART and to save resources.</P>
Kim Sun Bean,Ryoo Seungeun,Huh Kyungmin,Joo Eun-Jeong,Kim Youn Jeong,Choi Won Suk,Kim Yae-Jean,Yoon Young Kyung,Heo Jung Yeon,Seo Yu Bin,Jeong Su Jin,Park Dong-ah,Yu Su-Yeon,Lee Hyeon-Jeong,Kim Jimin 대한감염학회 2021 Infection and Chemotherapy Vol.53 No.1
Despite the global effort to mitigate the spread, coronavirus disease 2019 (COVID-19) has become a pandemic that took more than 2 million lives. There are numerous ongoing clinical studies aiming to find treatment options and many are being published daily. Some effective treatment options, albeit of variable efficacy, have been discovered. Therefore, it is necessary to develop an evidence-based methodology, to continuously check for new evidence, and to update recommendations accordingly. Here we provide guidelines on pharmaceutical treatment for COVID-19 based on the latest evidence.
( Sun Bean Kim ),( Do Kyung Kim ),( Sun Jeong Byun ),( Ji Hye Park ),( Jin Young Choi ),( Young Nyun Park ),( Do Young Kim ) 대한간학회 2015 Clinical and Molecular Hepatology(대한간학회지) Vol.21 No.4
Peliosis hepatis is a rare condition that can cause hepatic hemorrhage, rupture, and ultimately liver failure. Several authors have reported that peliosis hepatis develops in association with chronic wasting disease or prolonged use of anabolic steroids or oral contraceptives. In this report we describe a case in which discontinuation of steroid therapy improved the condition of a patient with peliosis hepatis. Our patient was a 64-year-old woman with a history of long-term steroid treatment for idiopathic thrombocytopenic purpura . Her symptoms included abdominal pain and weight loss; the only finding of a physical examination was hepatomegaly. We performed computed tomography (CT) and magnetic resonance imaging (MRI) of the liver and a liver biopsy. Based on these findings plus clinical observations, she was diagnosed with peliosis hepatis and her steroid treatment was terminated. The patient recovered completely 3 months after steroid discontinuation, and remained stable over the following 6 months. (Clin Mol Hepatol 2015;21:387-392)
Interim Guidelines on Antiviral Therapy for COVID-19
Kim Sun Bean,Huh Kyungmin,Heo Jung Yeon,Joo Eun-Jeong,Kim Youn Jeong,Choi Won Suk,Kim Yae-Jean,Seo Yu Bin,Yoon Young Kyung,Ku Nam Su,Jeong Su Jin,Kim Sung-Han,Peck Kyong Ran,Yeom Joon Sup 대한감염학회 2020 Infection and Chemotherapy Vol.52 No.2
Since the first case was reported in Wuhan, Hubei Province, China on December 12, 2019, Coronavirus disease 2019 (COVID-19) has spread widely to other countries since January 2020. As of April 16, 2020, 10635 confirmed cases have been reported, with 230 deaths in Korea. COVID-19 patients may be asymptomatic or show various clinical manifestations, including acute symptoms such as fever, fatigue, sore throat; pneumonia presenting as acute respiratory distress syndrome; and multiple organ failure. As COVID-19 has such varied clinical manifestations and case fatality rates, no standard antiviral therapy regimen has been established other than supportive therapy. In the present guideline, we aim to introduce potentially helpful antiviral and other drug therapies based on in vivo and in vitro research and clinical experiences from many countries.
Kim Sun Bean,Kim Jimin,Huh Kyungmin,Choi Won Suk,Kim Yae-Jean,Joo Eun-Jeong,Kim Youn Jeong,Yoon Young Kyung,Heo Jung Yeon,Seo Yu Bin,Jeong Su Jin,Yu Su-Yeon,Peck Kyong Ran,Choi Miyoung,Yeom Joon Sup 대한감염학회 2021 Infection and Chemotherapy Vol.53 No.2
Neutralizing antibodies targeted at the receptor-binding domain of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein have been developed and now under evaluation in clinical trials. The US Food and Drug Administration currently issued emergency use authorizations for neutralizing monoclonal antibodies in non-hospitalized patients with mild to moderate coronavirus disease 2019 (COVID-19) who are at high risk for progressing to severe disease and/or hospitalization. In terms of this situation, there is an urgent need to investigate the clinical aspects and to develop strategies to deploy them effectively in clinical practice. Here we provide guidance for the use of anti-SARS-CoV-2 monoclonal antibodies for the treatment of COVID-19 based on the latest evidence.
Monkeypox: the resurgence of forgotten things
Kim Sun Bean,Jung Jaehun,백경란 한국역학회 2022 Epidemiology and Health Vol.44 No.-
Monkeypox, a rare zoonotic disease, is prevalent primarily in Central and Western Africa. However, as the 2022 monkeypox outbreak is the first incidence of widespread community transmission outside Africa, monkeypox is emerging as a worldwide concern. Monkeypox is caused by the monkeypox virus, which belongs to the genus orthopoxvirus and presents as a vesicular-pustular disease that may be preceded by fever, malaise, and other constitutional symptoms. If present, lymphadenopathy may distinguish it from chickenpox or smallpox. However, contrary to previous manifestations, most monkeypox patients presented with atypical features during the 2022 outbreak. Monkeypox is usually a self-limiting disease with symptoms lasting between 2 and 4 weeks and is mainly transmitted when a person is in contact with an infected animal, person, or fomites contaminated with the virus. Very few treatment options are available for treating this disease. Tecovirimat has been licensed in some countries for the treatment of smallpox and monkeypox infections. Two other medications, cidofovir and brincidofovir, were effective against poxviruses in in vitro and animal studies, but data on human cases of monkeypox are limited. Although Imvamune (JYNNEOS), a vaccine against monkeypox, is authorized in the United States, there are currently no established routine vaccination programs. Current preventive strategies focus on the detection of probable cases and containment of the outbreak through the implementation of selected ring vaccination programs. Fundamental principles to prevent the spread of monkeypox, including maintaining personal hygiene and avoiding close contact with symptomatic patients, are of paramount importance.
Kim Tark,Choi Min Joo,Kim Sun Bean,Kim Jin Yong,이재갑,Oh Hong Sang,Lee Heeyoung,Yoon Young Kyung 대한감염학회 2020 Infection and Chemotherapy Vol.52 No.3
The dynamic nature of coronavirus disease 2019 (COVID-19) pandemic requires us to be efficient and flexible in resource utilization. The strategical preparedness and response actions of the healthcare system are the key component to contain COVID-19 and to decrease its case fatality ratio. Depending on the epidemiological situation, each medical institution should systematically share the responsibility for patient screening, disposition and treatment according to clinical severity. To overcome fast-paced COVID-19 pandemic, the government should be rapidly ready and primed for action according to the specific transmission scenario.